v**********m
发帖数: 5516 | 1 马后炮，在我的个人小抄本里找到这篇文章
=============
On 11 May 2011, BioSante's share price closed at $2.33. But by 25 May, two
weeks later, it shot up to $2.92:
1. While the stock market began its May-June descent...
2. On the heels of reporting a huge loss in Q1...
3. And on no news.
Scouring the news including SEC filings, these events stand-out:
* 10 May BioSante reported "BioSante 1Q loss widens on costs". The
company reported losing $17.3M or 20 cents per share and zero revenue. Yet
other than a... 阅读全帖 |
|
v**********m
发帖数: 5516 | 2 July 18, 2011 07:55 AM Eastern Daylight Time
BioSante Pharmaceuticals Announces Management Team Additions
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D.,
as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M.
Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed
this new role effective today. Ms. Adams assumed her new role effective in
May 2011.
“W... 阅读全帖 |
|
v**********m
发帖数: 5516 | 3 9:04AM BioSante prices public offering of common stock at $3.00/share;
proceeds expected to be ~ $45 mln (BPAX) 3.10 : Co announced the pricing of
its previously announced underwritten public offering of 16.0 mln shares of
its common stock, offered at a price of $3.00/share to the public. The net
proceeds to BioSante from this offering are expected to be ~$45.0 mln, after
deducting underwriting discounts and commissions, and other estimated
offering expenses payable by BioSante. All of the share... 阅读全帖 |
|
v**********m
发帖数: 5516 | 4 9:04AM BioSante prices public offering of common stock at $3.00/share;
proceeds expected to be ~ $45 mln (BPAX) 3.10 : Co announced the pricing of
its previously announced underwritten public offering of 16.0 mln shares of
its common stock, offered at a price of $3.00/share to the public. The net
proceeds to BioSante from this offering are expected to be ~$45.0 mln, after
deducting underwriting discounts and commissions, and other estimated
offering expenses payable by BioSante. All of the share... 阅读全帖 |
|
d******8
发帖数: 1972 | 5 h前几天2.55买了一些，不知是好消息还是坏消息？今天的交易量比较大，下跌趋势，但和这几天大盘相比，还是很坚挺。
更新。
多亏安排顶光头的文章，看完后就一直盯着，感觉不对，跌破2.45.就应该卖了，犹豫一会就下到了2.2下，后来在2.17卖了。
ttp://www.thestreet.com/story/11345313/1/biosante-pharma-readying-release-of
-female-viagra-study-results.html
LINCOLNSHIRE, Ill. (TheStreet) --BioSante Pharmaceuticals(BPAX_) will tell
us soon whether or not its testosterone gel improves the sex lives of
certain women.
A scheduled presentation Wednesday by BioSante executives at an investor
conference was cancelled this mor... 阅读全帖 |
|
v**********m
发帖数: 5516 | 6 爆雷全文
BioSante Pharmaceuticals Announces Proposed Public Offering of Common Stock
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. All of the shares in the
offering will be sold by BioSante. The offering is subject to market
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms ... 阅读全帖 |
|
|
|
d******8
发帖数: 1972 | 9 BioSante Pharmaceuticals Announces Results from LibiGel® Efficacy Trials
LibiGel does not achieve primary endpoints in the treatment of hypoactive
sexual desire disorder in postmenopausal women |
|
a*****h
发帖数: 484 | 10 再贡献一个今天出消息过一段时间可能n*的匹克,感觉有戏，YMYD
BPAX(2.25 +0.4701 (+26.41%))
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase
III ProgramFont size: A | A | A8:00 AM ET 8/13/09 | BusinessWire
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced positive
safety data in its ongoing LibiGel Phase III clinical development program.
BioSante reported that with over 1,250 women enrolled and almost 825 women-
years of exposure in its LibiGel Phase III clinical development program,
the... 阅读全帖 |
|
v**********m
发帖数: 5516 | 11 重要的时间点和market 都能在这篇文章里找到。
================
http://www.investorideas.com/CO/BPAX/news/2011/07151.asp
Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (
NASDAQ: BPAX), Discusses the Potential of Future Partners or Acquisition
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com
newswire.com) Investorideas.com, an investor research portal covering
leading sectors including biotech and pharma stocks, features an exclusive Q
&A interview with Mr. Stephen M... 阅读全帖 |
|
p********e
发帖数: 1960 | 12 http://seekingalpha.com/article/287381-the-two-very-best-biotec
The market correction has been a gift.
After combing through low-flyer biotechs for over one year, I am convinced
that the two very best biotechs under $3/share are: BioSante Pharmaceuticals
(BPAX) and Antares Pharma (AIS). If I was pressed to add a third stock to
my list, it would be AEterna Zentares (AEZS), but for now I will stick with
only two. The basis for my researched conclusion is as follows:
BioSante
BioSante recently gave... 阅读全帖 |
|
s**********9
发帖数: 846 | 13 BioSante Pharmaceuticals (BPAX) To Raise $25.1M In Offering
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) received commitments from
several institutional investors to purchase $25.1 million of securities in a
registered direct offering. BioSante expects to receive ...
Holly crap! |
|
s**********9
发帖数: 846 | 14 BioSante Pharmaceuticals (BPAX) To Raise $25.1M In Offering
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) received commitments from
several institutional investors to purchase $25.1 million of securities in a
registered direct offering. BioSante expects to receive ...
Holly crap! |
|
f**********g
发帖数: 2252 | 15 Investors Hopeful for Blockbusters From BioSante and Sunesis
1 hours 15 minutes ago - Marketwire via Comtex
MarketwireRecent studies have shown that the chances of FDA approval for
early stage drugs is dropping significantly. Although it remains an exciting
time in the biotech sector with several potential blockbusters working
their way through the regulatory process, now, more than ever, many analysts
are urging investors to use caution. The Bedford Report examines the
outlook for companies in ... 阅读全帖 |
|
p********e
发帖数: 1960 | 16 DNDN, KERX, BPAX, CHTP, OPXA
http://seekingalpha.com/article/286963-5-cheap-biotech-stocks-t
Most biotech stocks have experienced very sharp drops as the markets have
plummeted over economic concerns. However, biotechs are not as economically
sensitive as other companies and therefore are likely to rebound sharply in
the coming days. These dirt cheap biotech companies all have interesting
products in the pipeline which could become major catalysts in the future.
The lower priced stocks tend to h... 阅读全帖 |
|
t**u
发帖数: 1572 | 17 Interim result will be checked every 3 months according to seekingalpha news.
There was an interim in May, but the result was reported in June. So there
should be an interim in August. But I don't know when the result will be
disclosed. But there should be no worry about the interim safety results.
============
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
by: Kaushik Paul
May 10, 2011 | about: BPAX
By May 2011, an independent Data Monitoring Committee (DMC) is expect... 阅读全帖 |
|
l*********m
发帖数: 16971 | 18 BPAX：FDA批准一个药, phase 3 一个，phase 1&2一堆， 1：6 reverse split on 6/4
, book value $2.2, $2是底，探过三次底，经常一蹿就是50%，前天2.16 我买了3400股
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health and oncology. BioSante is developing a
portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials
currently on-going. Four of these vaccines have been granted Orphan Drug
designation by the U.S. Food and Drug Administration (FDA). |
|
c********n
发帖数: 1793 | 19 在这里，我从来不会针对你和其他的人评论。
我是说ANIP公司和管理者比较忽悠人。
我是BPAX的股东，亏损超过90%。我曾和这个ANIP的CEO也就是原来BPAX通过电话，不曾
有深入的了解。
但是知道一点他们的操作非常的不地道，BPAX差不多要DeList，最后没有办法只好收购
一个小公司改了代号。
其他的事情，建议你们自己要适当地做点调查和分析，这个很有必要，尤其是对长线投
资的朋友。
以上是我的逆耳忠言。祝大家发财！
links:
BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter：
http://www.businesswire.com/news/home/20130621005122/en/BioSant
他们不是一次收到delisting有关的信件。 |
|
w******i
发帖数: 1476 | 20 24% increase
LINCOLNSHIRE, Ill. (AP) -- BioSante Pharmaceuticals Inc. said Thursday its
potential pancreatic cancer treatment met key goals in a midstage study.
The company's stock surged 32 cents, or 16 percent, to $2.35 in premarket
trading.
The company said a newly published study showed the vaccine increased the
median survival rate of patients by more than 25 percent to 24.8 months. The
results were published in the February issue of the Annals of Surgery and
involved 60 patients undergoing... 阅读全帖 |
|
w******i
发帖数: 1476 | 21 24% increase
LINCOLNSHIRE, Ill. (AP) -- BioSante Pharmaceuticals Inc. said Thursday its
potential pancreatic cancer treatment met key goals in a midstage study.
The company's stock surged 32 cents, or 16 percent, to $2.35 in premarket
trading.
The company said a newly published study showed the vaccine increased the
median survival rate of patients by more than 25 percent to 24.8 months. The
results were published in the February issue of the Annals of Surgery and
involved 60 patients undergoing... 阅读全帖 |
|
y*****l
发帖数: 5997 | 22 7:55AM BioSante announces lifting of clinical hold on GVAX prostate cancer
vaccine (BPAX) 3.01 : Co announces that the FDA's clinical hold on the GVAX
Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted
by FDA. Manufacturing of new GVAX Prostate is complete, and planning for a
Phase II clinical trial at the Johns Hopkins Kimmel Cancer Center is
underway. BioSante funded the manufacturing of GVAX Prostate, and the trial
will be supported in part by the Prostate Cancer Fou... 阅读全帖 |
|
|
|
l*********m
发帖数: 16971 | 25 来自主题: _pennystock版 - BPAX BPAX：FDA批准一个药, phase 3 一个，phase 1&2一堆， 1：6 reverse split on 6/4
, book value $2.2, $2是底，探过三次底，经常一蹿就是50%，前天2.16 我买了3400股
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health and oncology. BioSante is developing a
portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials
currently on-going. Four of these vaccines have been granted Orphan Drug
designation by the U.S. Food and Drug Administration (FDA). |
|
w****r
发帖数: 245 | 26 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
w****a
发帖数: 12 | 27 Biotech Calendar: 2011 FDA Drug Approvals
05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval decision date: May 30, 2011
GlaxoSmithKline(GSK_) and Valeant Pharmaceuticals(VRX_... 阅读全帖 |
|
K********g
发帖数: 9389 | 28 既然成为板斧了，那就为股版添点东西。
下面的医药股是2011年11-2012年1月的FDA的NDA待审批的。大家记住，任何药股的NDA
风险都比较大，要学会炒药股，切忌去赌药股的NDA.下面带星号的我觉得还可以值得研
究。
12/8/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision
on Anturol Gel for overactive bladder
12/7/2011 AFFYMAX INC AFFY Peginesatide (NDA) FDA panel to
review Peginesatide for anemia associated with chronic renal failure
***12/3/2011 Incyte Corporation INCY Ruxolitinib (NDA) FDA
decision on Ruxolitinib as... 阅读全帖 |
|
K********g
发帖数: 9389 | 29 既然成为板斧了，那就为股版添点东西。
下面的医药股是2011年11-2012年1月的FDA的NDA待审批的。大家记住，任何药股的NDA
风险都比较大，要学会炒药股，切忌去赌药股的NDA.下面带星号的我觉得还可以值得研
究。
12/8/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision
on Anturol Gel for overactive bladder
12/7/2011 AFFYMAX INC AFFY Peginesatide (NDA) FDA panel to
review Peginesatide for anemia associated with chronic renal failure
***12/3/2011 Incyte Corporation INCY Ruxolitinib (NDA) FDA
decision on Ruxolitinib as... 阅读全帖 |
|
j******y
发帖数: 700 | 30 sounds a nice pick!
The following seven securities will be added to the Index: Amarin
Corporation plc (Nasdaq:AMRN), BioSante Pharmaceuticals, Inc. (Nasdaq:BPAX),
Endocyte, Inc. (Nasdaq:ECYT), Grifols, S.A.(Nasdaq:GRFS), Oncothyreon, Inc.
(Nasdaq:ONTY), SciClone Pharmaceuticals, Inc.(Nasdaq:SCLN) and Sagent
Pharmaceuticals, Inc. (Nasdaq:SGNT). |
|
d******8
发帖数: 1972 | 31 前几天2.55买了一些，不知是好消息还是坏消息？今天的交易量比较大，下跌趋势，但
和这几天大盘相比，还是很坚挺。 |
|
l****g
发帖数: 5080 | 32 这东西需求大吗？地球是男性主导，要是女士需求比较大，我是一定会闪，钥匙哪里强
得过锁头。 |
|
|
|
d******8
发帖数: 1972 | 35 今天真正经历了跳水，在犹豫卖的过程中，从2.5 到了2.2
2.17 抛掉，现在0.5. |
|
t***y
发帖数: 2276 | 36 哎呀，僵死叫你们买，没有人买；
5块以下的股票，叫你们不要沾，你们非要买。那个DANG涨翻天，我也不碰它。 |
|
|
c********n
发帖数: 127 | 38 why not touching Dang at 4.40? |
|
l*********m
发帖数: 16971 | 39 0.44 now
AIS is related with it. |
|
a*********2
发帖数: 932 | 40 it shocked me, because BPAX was in my candidate list. |
|
h****l
发帖数: 473 | 41 Robbins Umeda LLP Announces Investigation Of BioSante Pharmaceuticals, Inc.
幸好昨天没进，还是娱乐仓吧，赚个buffet，以后不乱喊了。娱乐仓的早盘可以入点，
继续冷眼看BPAX如何表演。 |
|
h****l
发帖数: 473 | 42 The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into
Possible Securities Laws Violations by BioSante Pharmaceuticals, Inc.
看起来官司缠身 |
|
m******i
发帖数: 834 | 43 A round up of this week's nanotech news featuring CSIRO, BioSante,
Cientifica and more.
General company news
CSIRO has receivedAUD $36.2 mn (ERO$ 22 mn) from the Australian
government to establish aniche manufacturing facility for exploiting
nanotechnology andmaterials research. The flagship project aims to create a
new wave ofniche industries and boost the high-value segment of the country'
smanufacturing sector. "Nanotechnology is arguably the biggestopportunity
Australian manufacturing has |
|
w***y
发帖数: 2537 | 44 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ER for week August 2-6
发信站: BBS 未名空间站 (Sun Aug 1 22:47:17 2010, 美东)
Monday, Aug. 2
10 a.m.: ISM Manufacturing index on business activity in July, released by
the Institute for Supply Management.
10:15 a.m. Federal Reserve Chairman Ben Bernanke speaking on "challenges for
the economy and state governments."
4 p.m. Treasury Secretary Timothy Geithner speaking on the next steps for
financial reform.
Tuesday, Aug. 3
8:30 a.m.: P... 阅读全帖 |
|
N***i
发帖数: 2063 | 45 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ERs for week Aug 9-13
发信站: BBS 未名空间站 (Sat Aug 7 22:26:20 2010, 美东)
Monday, Aug. 9
Scheduled for around noon: President Obama to deliver remarks at University
of Texas in Austin.
No data scheduled.
Tuesday, Aug. 10
House returns for one day to vote on state aid bill.
9 a.m.: Federal Reserve's Federal Open Market Committee meets on interest
rate and monetary policy. Statement to be released at 2:15 p.m., at Fed
headquarters.
8... 阅读全帖 |
|
y*****l
发帖数: 5997 | 46 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological order based on the drug approval decision date. Information on pending FDA advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval... 阅读全帖 |
|
y*****l
发帖数: 5997 | 47 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Stock quotes in this article:SPPI, CTIC, TSPT, SGEN, ANX, PATH, OPTR
http://finviz.com/screener.ashx?v=341&t=SPPI,CTICD,TSPT,SGEN,AN
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advis... 阅读全帖 |
|
|
y*****l
发帖数: 5997 | 49 你买BPAX, 我没事说SNSS干嘛。
BPAX 11/14
Teva Pharmaceuticals(TEVA) and BioSante Pharmaceuticals(BPAX)
Drug/indication: Bio-T-Gel for male low testosterone levels
Approval decision date: Nov. 14, 2011 |
|
f**********g
发帖数: 2252 | 50 http://www.bloomberg.com/news/2011-07-11/biosante-s-female-sex-
A “very conservative” estimate may be a licensing deal for $100 million
plus future royalties, or an acquisition in the range of $300 million to $
500 million, Simes said. He acknowledged a higher price may be possible with
“a significant premium” over the company’s market cap of about $337
million as of July 8. |
|
